anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses genes of staphylococcal enterotoxin A and the new application of the encoding protein of the genes. Proved by experiments of the inventor, the genes of staphylococcal enterotoxin A can obviously improve the reactivity of animals on DNA vaccines, and thus, the genes of the staphylococcal enterotoxin A can be used as immunogenicity enhancement adjuvant for DNA or recombinant subunit vaccines. The genes of the staphylococcal enterotoxin A enable the immunogenicity of various DNA vaccines, such as the DNA vaccines of hepatitis B virus surface antigens, the DNA vaccines of malaria multi-epitope antigens, etc., to be enhanced. Thus, genes of the staphylococcal enterotoxin A have broad spectrum performance, which is a kind of valuable immunogenicity enhancement adjuvant of the DNA vaccines. The staphylococcal enterotoxin A enables the immunogenicity of various recombinant subunit vaccines to be enhanced, and is a valuable immunogenicity enhancement adjuvant of the recombinant subunit vaccines. The genes of the staphylococcal enterotoxin A and the encoding protein thereof have significance to the preparation and the application of the DNA vaccines and the recombinant subunit vaccines.
Chronic musculoskeletal pain is defined as persistent or recurrent pain lasting more than 3 months. Chronic pain is a complex and disabling physiological and psychosocial disorder that does not provide an adaptive or protective purpose. In chronic pain, the precipitating event (e.g., fracture, sprain, trauma) is healed, and yet excessive pain remains. In Immersive Virtual Reality (IVR) people experience a three-dimensional, computer-generated environment via a computer headset. IVR has been used to treat acute pain, but there have been few focused studies on the effects of IVR on chronic pain. When people with chronic pain are in IVR, they become unaware of their body and tend to move normally. We would like to test to see if IVR has a lasting effect in this study. Thus, IVR has strong potential as an additional tool in an arsenal of treatments for chronic pain. This study will examine if IVR can reduce pain and other symptoms in people with chronic pain.
PURPOSE: Provided are natural phenol and polyphenol compounds which have prevention and treatment effects on male dysgenesia by inactivating endocrine disruptors, such as dioxin, that cause male dysgenesia. And methods for extracting and purifying natural phenol and polyphenol compounds and a pharmaceutical composition containing them are also provided . CONSTITUTION: Natural phenol and polyphenol are prepared by using fruits of the family Rosaceae such as apple, peach, pear, and coffee bean, cacao bean and grape seed. A first method of using an apple is characterized by the next steps: i) compressing a clean apple to obtain juice and treating the juice with pectinase; ii) adsorbing filtered juice into columns and cleansing the juice; iii) obtaining condensed solution with 65% ethanol and drying the solution to obtain powdered extract of an apple. A second method of using coffee comprises the steps: i) grinding coffee bean into the size of 5 mm and eliminating foreign substances; and ii) extracting condensed coffee solution with deionized water and drying the solution to obtain powdered coffee extracts. A third method of using cacao bean includes the steps: i) extracting solution from dried cacao beans or their skins with 60% acetone for 24 hours; ii) centrifuging the obtained solution and obtaining supernatant and remnants; iii) adding acetone to the remnants again and repeating the extraction processes four times; iv) condensing and filtering the supernatant and removing chlorophyll from the supernatant; and v) obtaining cacao extracts by using acetone.
The invention discloses an adeno-associated virus vector for expressing a miniature dystrophin gene and application thereof. The amino acid sequence of the human miniature Dystrophin mu Dystrophin is shown in SEQ ID NO. 1. The sequence of the gene for encoding the human miniature Dystrophin mu Dystrophin is shown as SEQ ID No. 3. Based on the above, we can efficiently produce the miniature dystrophin protein in the C2C12 muscle cells by using the muscle tissue specific promoter. Finally, AAV9 viral vectors and recombinant adeno-associated viruses with high-efficiency tissue specific expression of the miniature dystrophin are constructed, muscle cells can be efficiently transduced in a DMD disease model, and functional truncated dystrophin can be efficiently expressed, so that the treatment target of DMD is realized.
The considerable death rates and lack of symptoms in early stages of gastric cancer (GC) make it a major health problem worldwide. One of the most prominent risk factors is infection with Helicobacter pylori. Many biological processes, including those linked with cell death, are disrupted in GC. The cellular "self-digestion" mechanism necessary for regular balance maintenance, autophagy, is at the center of this disturbance. Misregulation of autophagy, however, plays a role in the development of GC. In this review, we will examine how autophagy interacts with other cell death processes, such as apoptosis and ferroptosis, and how it affects the progression of GC. In addition to wonderful its role in the epithelial-mesenchymal transition, it is engaged in GC metastasis. The role of autophagy in GC in promoting drug resistance stands out. There is growing interest in modulating autophagy for GC treatment, with research focusing on natural compounds, small-molecule inhibitors, and nanoparticles. These approaches could lead to breakthroughs in GC therapy, offering new hope in the fight against this challenging disease.
BACKGROUND: Hepatocellular carcinoma (HCC) is highly malignant with a dismal prognosis, although the available therapies are insufficient. No efficient ubiquitinase has been identified as a therapeutic target for HCC despite the complicating role that of proteins ubiquitination plays in the malignant development of HCC.
METHODS: The expression of ubiquitin carboxyl terminal hydrolase L5 (UCHL5) in HCC tumor tissue and adjacent normal tissue was determined using the cancer genome atlas (TCGA) database and was validated using real-time quantitative polymerase chain reaction (RT-qRCR), Western blot and immunohistochemistry (IHC), and the relation of UCHL5 with patient clinical prognosis was explored. The expression of UCHL5 was knocked down and validated, and the effect of UCHL5 on the biological course of HCC was explored using cellular assays. To clarify the molecular mechanism of action of UCHL5 affecting HCC, expression studies of Adenosine triphosphate adenosine triphosphate (ATP), extracellular acidification (ECAR), and glycolysis-related enzymes were performed. The effects of UCHL5 on β-catenin ubiquitination and Wnt signaling pathways were explored in depth and validated using cellular functionalities. Validation was also performed in vivo.
RESULTS: In the course of this investigation, we discovered that UCHL5 was strongly expressed in HCC at both cellular and tissue levels. The prognosis of patients with high UCHL5 expression is considerably worse than that of those with low UCHL5 expression. UCHL5 has been shown to increase the degree of glycolysis in HCC cells with the impact of stimulating the proliferation and metastasis of HCC cells in both in vivo and in vitro. UCHL5 downregulates its degree of ubiquitination by binding to β-catenin, which activates the Wnt/β-catenin pathway and accelerates HCC cell glycolysis. Thereby promoting the growth of the HCC.
CONCLUSIONS: In summary, we have demonstrated for the first time that UCHL5 is a target of HCC and promotes the progression of hepatocellular carcinoma by promoting glycolysis through the activation of the Wnt/β-catenin pathway. UCHL5 may thus serve as a novel prognostic marker and therapeutic target for the treatment of HCC.
BACKGROUND: The use of digital pain management interventions has grown since the Covid 19 pandemic. The aim of this study was to systematically review and synthesise evidence from qualitative studies regarding the experiences of individuals with chronic pain participating in digital pain management interventions in primary care and community settings.
METHODS: Fourteen databases were searched, as well as citation tracking and hand-searching reference lists of included articles. The latest search was completed by 07/07/2023. Qualitative studies of patient and carer perspectives of digital pain management interventions for adults aged 18 and over with non-malignant chronic pain were included. All studies were appraised for quality using the Critical Appraisal Skills Programme Qualitative Checklist. A narrative synthesis approach was used to synthesise the findings. Normalisation Process Theory was used to understand how individuals with chronic pain make sense of digital pain management interventions and incorporate knowledge, skills and strategies learnt into their day-to-day lives.
RESULTS: Eleven studies, encompassing both digital applications for use on smartphones/ mobile devices and user-directed online modular programmes, were included in the synthesis. Three main themes and related subthemes were identified from the included studies: 1) Making sense of the digital intervention (Subthemes: Tailoring to user's needs; Human contact and support; Accessibility of the digital intervention; Personal and environmental factors affecting engagement with digital interventions); 2) Initiating and Maintaining Behaviour Change (Subthemes: Planning activity; Being active); and 3) Personal Growth (Subthemes: Gaining understanding and skills; Gaining and acting on feedback; Negotiating a new relationship with pain).
CONCLUSION: Recommendations. The key recommendations from our findings are that digital pain management interventions should provide: Specific and tailored information for individual participants.Focus on changing attitudes and behaviours and reframing perceptions of pain.Structured goal setting with prompts to review goals.Potential healthcare professional support alongside the digital intervention.Limitations of the review. To reduce bias, it would have been preferable for more than one author to independently fully analyse each paper and to identify themes and sub-themes. Instead, the identified themes and sub-themes were discussed with two other authors in the team (ES, LW) to reach a consensus view on final themes and sub-themes. One author (JS) received a Research Internship and Research Initiation Award funded by NIHR Applied Research Collaboration (ARC) Wessex (https://www.arc-wx.nihr.ac.uk/) and NHS England (https://www.england.nhs.uk/). The protocol for this review was registered with the National Institute of Health Research (NIHR) PROSPERO international database for registering systematic reviews (PROSPERO Registration Number CRD42021257768).
The present application provides an apparatus for outputting data associated with a procedure, which may include a processor that may be configured to be capable of receiving first patient data prior to the procedure. The processor may be configured to generate the transformation prior to the procedure. The processor may be configured to receive second patient data during the procedure and apply the transformation based on the received second patient data satisfying a condition of the transformation. The transformation may be applied to the second patient data to derive third patient data. The third patient data may include the second information and contextual information about the second information. For example, the third patient data may include an alert to a healthcare professional having a current value of the biomarker and an indication of the magnitude and/or nature of the current value deviating from baseline.
Patients will receive IVA and OA per Group A. In addition, patients will stay on clear fluids and self-administer a 2L polyethylene glycol MBP orally, between 1500 and 2300 hours on the day before surgery.
Hemangioma is a common vascular neoplasm that arises in the head and neck regions but is rare in the petrous bone. We report the first case of a solitary cavernous hemangioma in the mastoid antrum. A 68-year-old woman visited our hospital with a complaint of tinnitus without any other symptoms. Tinnitus of the right ear occurred especially when the patient yawned or swallowed. Both tympanic membranes appeared normal on otoscopic examination. On pure-tone audiometry, mild hearing loss up to 25 dB was detected in the right ear. Temporal bone computed tomography revealed a 7.0 mm × 4.5 mm × 5 mm, solitary soft tissue mass in the aditus ad antrum. Excisional biopsy was performed under general anesthesia through the canal wall as in a mastoidectomy. The mass was completely removed without any bleeding or ossicular chain damage. The mass was confirmed as a cavernous hemangioma. During follow-up, the patient's tinnitus and right low-tone hearing loss improved. No solitary hemangioma of the mastoid antrum has been reported previously. Surgical excision of the lesion appears to be proper treatment to achieve pathologic confirmation along with resolution of symptoms.
Benign rolandic epilepsy (BRE) is a common seizure disorder confined solely to children. The disorder is marked clinically by nocturnal generalized tonic-clonic seizures and diurnal seizures consisting of simple partial seizures consisting of brief unilateral facial clonic activity, dysphasia, and drooling. The EEG abnormalities are unique, consisting of generally high amplitude, centrotemporal spikes that are activated by sleep. The seizures typically begin in the first decade and almost always stop by age 16 years. The seizures are usually infrequent although clusters of seizures do occur. When the physician elects to treat, the seizures are usually easily controlled. This is a randomized, open label, active controlled, multi-center based clinical trial to determine the efficacy and safety of Topiramate comparing with Carbamazepine in Benign rolandic epilepsy. The study hypothesis is that topiramate will be more effective in treatment of Benign rolandic epilepsy than Carbamazepine, as evaluated by seizure-free rate at 24 weeks and Intellectual Functioning : KEDI-WISC (Korean Educational Development Institute Wechsler Intelligence Scale for Children-Revised) and is generally well-tolerated.

Topiramate (target dose) 4mg/kg/day, B.I.D, oral, for 24 weeks, carbamazepine(target dose) 30mg/kg/day, B.I.D, oral, for 24 weeks.
PURPOSE:To obtain a human cell-derived endothelin converting enzyme capable of converting big endothelin into endothelin. CONSTITUTION:The objective endothelin converting enzyme is composed of a fraction obtained by homogenizing a human cell of a human organ or tissue producing the endothelin such as the placenta, vascular endothelium, kidney or cerebrum as a raw material, separating and collecting the supernatant from the resultant homogenate, subjecting the prepared homogenate supernatant to ultracentrifugation, taking out its precipitate and fractionating the resultant cell membrane fraction. This fraction has about 270000 molecular weight and an optimum pH of 7.0-8.0. An effective means for searching for and developing an inhibitor of the converting enzyme as a means for preventing and treating various morbid states (diseases caused by a high concentration of the endothelin) induced by hypersecretion of endothelin, e.g. hypertension, airway constriction, ischemic cerebropathy and cardiopathy, nephropathy, circulatory insufficiency of various organs, e.g. the lung, liver or intestines or asthma by elucidating this converting enzyme.
Adults with obesity will be asked to perform the obstacle crossing intervention for adults with obesity for reducing falls risk. This will involve crossing obstacles of different heights under five conditions: initial baseline walking on flat ground, crossing three obstacle heights, and final baseline walking on flat ground for a total of 25 trials. Spatio-temporal gait parameters will be collected using a gait carpet and body-worn sensors.
Patients receive CYT107 IM on days 1, 8, 15, and 22, and atezolizumab IV over 60 minutes on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI scans, and collection of blood and stool samples on study. Patients may also undergo tumor biopsy at screening and on study.
A product produced in a PVD method is described, which consists of thin plane- parallel structures having a thickness in the range from 20 to 2000 nm and small dimensions in the range below one mm. Production is carried out by condensation of silicon suboxide onto a carrier passing by way of the vaporisers. The carrier is pre-coated, before condensation of the silicon suboxide, with a soluble, inorganic or organic separating agent in a PVD method. All steps, including that of detaching the product by dissolution, can be carried out continuously and simultaneously at different locations. As final step, the SiOy may be oxidised to SiO2 in an oxygen-containing gas at atmospheric pressure and temperatures of more than 200~C or SiOy may be converted to SiC at the surface of the plane-parallel structures in a carbon- containing gas at from 500~C to 1500~C. The products produced in that manner are distinguished by high uniformity of thickness.
This study introduces a new method for modeling electrocardiogram (ECG)1 waveforms using Fractional Differential Equations (FDEs). By incorporating fractional calculus into the well-established McSharry model, the proposed approach achieves improved representation and high precision for a wide range of ECG waveforms. The research focuses on the impact of integrating fractional derivatives into Integer Differential Equation (IDE) models, enhancing the fidelity of ECG signal modeling. To optimize the model's unknown parameters, a combination of the Predictor-Corrector method for solving FDEs and genetic algorithms for optimization is utilized. The effectiveness of the fractional-order model is assessed through distortion metrics, providing a comprehensive evaluation of the modeling quality. Comparisons show that the fractional-order model outperforms the traditional McSharry IDE model in modeling quality and compression efficiency. It improves modeling quality by 48.40 % in MSE and compression efficiency by 23.18 % when applied on five beat types of MIT/BIH arrhythmia database. The fractional-order model demonstrates enhanced flexibility while preserving essential McSharry model characteristics, with fractional orders (α) ranging from 0.96 to 0.99 across five beat types.
BACKGROUND: Diarrheal disease remains a significant public health issue, particularly affecting young children and older adults. Despite efforts to control and prevent these diseases, their incidence continues to be a global concern. Understanding the trends in diarrhea incidence and the factors influencing these trends is crucial for developing effective public health strategies.
OBJECTIVE: This study aimed to explore the temporal trends in diarrhea incidence and associated factors from 1990 to 2019 and to project the incidence for the period 2020-2040 at global, regional, and national levels. We aimed to identify key factors influencing these trends to inform future prevention and control strategies.
METHODS: The eXtreme Gradient Boosting (XGBoost) model was used to predict the incidence from 2020 to 2040 based on demographic, meteorological, water sanitation, and sanitation and hygiene indicators. SHapley Additive exPlanations (SHAP) value was performed to explain the impact of variables in the model on the incidence. Estimated annual percentage change (EAPC) was calculated to assess the temporal trends of age-standardized incidence rates (ASIRs) from 1990 to 2019 and from 2020 to 2040.
RESULTS: Globally, both incident cases and ASIRs of diarrhea increased between 2010 and 2019. The incident cases are expected to rise from 2020 to 2040, while the ASIRs and incidence rates are predicted to slightly decrease. During the observed (1990-2019) and predicted (2020-2040) periods, adults aged 60 years and above exhibited an upward trend in incidence rate as age increased, while children aged < 5 years consistently had the highest incident cases. The SHAP framework was applied to explain the model predictions. We identified several risk factors associated with an increased incidence of diarrhea, including age over 60 years, yearly precipitation exceeding 3000 mm, temperature above 20 °C for both maximum and minimum values, and vapor pressure deficit over 1500 Pa. A decreased incidence rate was associated with relative humidity over 60%, wind speed over 4 m/s, and populations with above 80% using safely managed drinking water services and over 40% using safely managed sanitation services.
CONCLUSIONS: Diarrheal diseases are still serious public health concerns, with predicted increases in the incident cases despite decreasing ASIRs globally. Children aged < 5 years remain highly susceptible to diarrheal diseases, yet the incidence rate in the older adults aged 60 plus years still warrants additional attention. Additionally, more targeted efforts to improve access to safe drinking water and sanitation services are crucial for reducing the incidence of diarrheal diseases globally.
Arm 2: IBI311 (3-20 mg). Participants will receive 8 intravenous infusions of IBI311 with an interval of 3 weeks. Dose conversion was performed at week 12.
Trauma is a leading cause of mortality in the pediatric population. In 2008, the American Academy of Pediatrics noted that trauma accounts for more deaths than all other causes combined . Bleeding remains the most preventable cause of death after trauma. A major recent advance was the recognition that coagulation defects are greatly responsible for the disproportional mortality caused by bleeding. Managing coagulation defects has become a forefront issue in trauma and novel strategies proposed include hemostatic resuscitation, adoption of massive transfusion protocols and other innovations , most with little evidence to support them. The exception is the proposal to administer tranexamic acid (TXA) to bleeding adult trauma patients.

To date, no medical treatment has been shown to reduce mortality in the setting of pediatric trauma; however, this evidence does exist in adults. Bleeding and coagulopathy due to trauma are associated with mortality in both adults and children. Clinical research has demonstrated a reduction in trauma-related mortality with early use of TXA in adult patients in both civilian and military settings . In adult patients with hemodynamic instability and ongoing bleeding, TXA is expected to save 1 in 67 lives . There is no scientific or biological reason to suggest that a similar mortality benefit will not be seen in pediatric trauma. The investigators feel the incorporation of TXA into pediatric trauma management has the potential to also significantly reduce mortality in children and youths, without increasing adverse events. This review explores the hematologic differences and similarities between injured children and adults, and the idea that TXA may be a novel and promising treatment in pediatric hemorrhagic trauma despite the current lack of evidence for its use in this setting.

TXA is an antifibrinolytic that reversibly binds to plasminogen at the lysine binding site, thus preventing the binding of plasmin (ogen) to fibrin and the subsequent degradation of fibrin . It is a generic, inexpensive medication used to prevent fibrin breakdown and reduce bleeding in various clinical settings (including orthopedic and cardiovascular surgery, post-partum hemorrhage, gastrointestinal hemorrhage, epistaxis, certain ophthalmologic conditions and other obstetric/gynecologic emergencies)
Participants received 2.0 mg intravitreal aflibercept injection (IAI) every 4 weeks for the first 12 weeks, followed by additional 2.0 mg IAI every 8 weeks until week 48. Additionally, sham photodynamic therapy (PDT) treatments was administered as needed.